

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/I9281CE5C90EN.html>

Date: June 2018

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: I9281CE5C90EN

Abstracts

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018

SUMMARY

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Dermatology and Musculoskeletal Disorders which include indications Inflammation,

Rheumatoid Arthritis, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Asthma, Atopic Dermatitis, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

Furthermore, this report also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development

Immune System Key Ltd

Onspira Therapeutics Inc

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Ribomic Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles

anakinra - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-1510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nerofe - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Antagonize IL1B for Bronchiolitis Obliterans - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-130 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products**Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products****Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones****Featured News & Press Releases**

Apr 11, 2018: Kineret (anakinra) approved in the EU for the treatment of Still's disease

Mar 26, 2018: Drug reduces inflammation in stroke patients

Feb 23, 2018: Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still's disease

Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor

Nov 16, 2017: First patient randomized in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still's disease

May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease

Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Nov 01, 2015: Immune System Key: Nerofe's Triple Action

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Apr 01, 2015: Immune System Key: Clinical Trial: Phase I Dose Escalation Completed Successfully With Exciting Results

Apr 23, 2014: First treatment for babies with ultra-rare spectrum of auto inflammatory diseases now available in UK

Dec 06, 2013: First treatment for infants with ultra-rare spectrum of auto inflammatory diseases licensed in UK

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Immune System Key Ltd, H1 2018
Pipeline by Onspira Therapeutics Inc, H1 2018
Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
Pipeline by ProteoThera Inc, H1 2018
Pipeline by Ribomic Inc, H1 2018
Pipeline by Swedish Orphan Biovitrum AB, H1 2018
Pipeline by XL-protein GmbH, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Immune System Key Ltd

Onspira Therapeutics Inc

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Ribomic Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

I would like to order

Product name: Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/I9281CE5C90EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I9281CE5C90EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

